PubMed
Insulin-like growth factor-I and its binding proteins in sport and exercise medicine
Baxter, 2011
GH SecretagoguesResearch OnlyC
IGF-1 LR3
Long R3 IGF-1
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a recombinant analog of IGF-1 with an Arg3 substitution and a 13-amino acid N-terminal extension. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), resulting in a ~20–30 hour half-life (vs. 12–15 hours for native IGF-1) and significantly greater tissue exposure and anabolic potency. Research only; not FDA-approved.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 5
- Research grade
- C
- Experience
- 99
- Activity
- 49
Overall check-ins
Trackers & reports
Overview
About IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a recombinant analog of IGF-1 with an Arg3 substitution and a 13-amino acid N-terminal extension. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), resulting in a ~20–30 hour half-life (vs. 12–15 hours for native IGF-1) and significantly greater tissue exposure and anabolic potency. Research only; not FDA-approved.
- Category
- GH Secretagogues
- Regulatory status
- Research Only
- Also known as
- Long R3 IGF-1
- Self-reports
- 30
Community
What 30 users report
30 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 97% · Mixed 3% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
171
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Water retention
5
Self-reported dose per injection
Median bucket: 50–100 mcg · Most common: 10–25 mcg
Reports span 0–200 mcg
0–10
1
10–25
60
25–50
1
50–100
53
100–200
56
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 96% said they felt similar to their last entry, 4% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 153 days · Based on 28 repeat reporters
Research
Cited research (4)
Source
ClinicalTrials.gov
IGF-1 LR3 studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice
Engel et al., 2025
PubMed
Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration
Yavuz et al., 2025
Tools
Explore more
Explore
More ways to learn about IGF-1 LR3 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about IGF-1 LR3?
This page summarizes 30 anonymized self-reports from PeptIQ users who track IGF-1 LR3, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for IGF-1 LR3?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for IGF-1 LR3?
4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is IGF-1 LR3 safe to use?
This wiki does not assess safety or recommend use. IGF-1 LR3 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of IGF-1 LR3?
This wiki summarizes observational community reports and linked citations for IGF-1 LR3. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for IGF-1 LR3 for study-level context — not medical advice.
What is the legal status of IGF-1 LR3?
IGF-1 LR3 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of IGF-1 LR3?
Safety data quality for IGF-1 LR3 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on IGF-1 LR3?
This page links 4 indexed sources for IGF-1 LR3. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.